WO2003014728A1 - Medicaments contre l'hepatite c - Google Patents

Medicaments contre l'hepatite c Download PDF

Info

Publication number
WO2003014728A1
WO2003014728A1 PCT/JP2002/008175 JP0208175W WO03014728A1 WO 2003014728 A1 WO2003014728 A1 WO 2003014728A1 JP 0208175 W JP0208175 W JP 0208175W WO 03014728 A1 WO03014728 A1 WO 03014728A1
Authority
WO
WIPO (PCT)
Prior art keywords
hepatitis
protein
virus
antibody
absence
Prior art date
Application number
PCT/JP2002/008175
Other languages
English (en)
Japanese (ja)
Inventor
Seima Itami
Makoto Seki
Masahiro Kito
Yoshiharu Matsuura
Tatsuo Miyamura
Original Assignee
Mitsubishi Pharma Corporation
Japan As Represented By Director General Of Agency Of National Institute Of Infectious Diseases
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Pharma Corporation, Japan As Represented By Director General Of Agency Of National Institute Of Infectious Diseases filed Critical Mitsubishi Pharma Corporation
Priority to JP2003519409A priority Critical patent/JP4221292B2/ja
Publication of WO2003014728A1 publication Critical patent/WO2003014728A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne un procédé permettant une recherche systématique d'une substance inhibant la liaison de la protéine E2/NS1 du virus de l'hépatite C avec un anticorps présentant une affinité pour cette même protéine. Une première opération consiste à (1) mettre la protéine E2/NS1 du virus de l'hépatite C en contact avec l'anticorps ci-dessus, en présence et en l'absence d'une substance de test. La dernière opération consiste enfin à (2) comparer la liaison de la protéine E2/NS1 du virus de l'hépatite C avec ledit anticorps, en présence et en l'absence de la substance de test. Ce procédé permet de disposer de nouveaux antiviraux permettant de prévenir notamment l'infection par le VHC.
PCT/JP2002/008175 2001-08-10 2002-08-09 Medicaments contre l'hepatite c WO2003014728A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003519409A JP4221292B2 (ja) 2001-08-10 2002-08-09 Ｃ型肝炎治療薬

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001243947 2001-08-10
JP2001-243947 2001-08-10

Publications (1)

Publication Number Publication Date
WO2003014728A1 true WO2003014728A1 (fr) 2003-02-20

Family

ID=19073953

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/008175 WO2003014728A1 (fr) 2001-08-10 2002-08-09 Medicaments contre l'hepatite c

Country Status (2)

Country Link
JP (1) JP4221292B2 (fr)
WO (1) WO2003014728A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006057339A1 (fr) * 2004-11-25 2006-06-01 Mitsubishi Pharma Corporation Procede de production d'anticorps

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999018198A1 (fr) * 1997-10-06 1999-04-15 Chiron S.P.A. Proteine receptrice cd81 de l'hepatite c

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999018198A1 (fr) * 1997-10-06 1999-04-15 Chiron S.P.A. Proteine receptrice cd81 de l'hepatite c

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALLANDER TOBIAS ET AL.: "Recombinant human monoclobal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81", vol. 81, no. 10, October 2000 (2000-10-01), pages 2451 - 2459, XP002939743 *
PILERI P. ET AL.: "Binding of hepatitic C virus to CD81", SCIENCE, vol. 282, 30 October 1998 (1998-10-30), pages 938 - 941, XP002092549 *
SHU KIKUCHI ET AL.: "Ketsueki baikai kansensho HCV", RINSHO TO KENKYU, vol. 76, no. 7, 1999, pages 1260 - 1266, XP002961752 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006057339A1 (fr) * 2004-11-25 2006-06-01 Mitsubishi Pharma Corporation Procede de production d'anticorps

Also Published As

Publication number Publication date
JP4221292B2 (ja) 2009-02-12
JPWO2003014728A1 (ja) 2004-11-25

Similar Documents

Publication Publication Date Title
WO1993000365A3 (fr) Polypeptides utilises dans la lutte contre le virus de l'hepatite c
ID21649A (id) Inhibitor serum protease, terutama virus hepatitis c ns3 protease
DK0458841T3 (da) Fremgangsmåde til anvendelse og fremstilling af peptider
WO2001070984A3 (fr) Anticorps de facteur anti-tissulaire a pouvoir anticoagulant ameliore
AU5285899A (en) Anti hepatitis c virus antibody and uses thereof
WO2003002749A3 (fr) Procedes servant a detecter simultanement des antigenes de hcv et des anticorps anti-hcv
WO1992017493A3 (fr) Peptides et melanges de peptides servant a detecter les anticorps diriges contre le virus de l'hepatite c
EP1305438A4 (fr) Particules de type virus ameliorees fondees sur une petite proteine d'enveloppe provenant de l'hepatite b (aghbs)
PT698216E (pt) Metodos de tipificacao do virus da hepatite c e reagentes para utilizar nestes
AU2001232267A1 (en) Remedies for hepatitis c
AU7602800A (en) Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
EP1111385A3 (fr) Complexe d'une enzyme et une protéine
WO2003087138A3 (fr) Procedes d'identification de facteurs polypeptidiques ayant une interaction avec l'arn
WO2002062959A3 (fr) Traitement du virus de l'hepatite b
WO1996035717A3 (fr) Substrats clivables, solubles, de la protease du virus de l'hepatite c
WO2002060954A8 (fr) Materiaux et procedes destines au traitement de l'hepatite c
AUPQ810900A0 (en) Viral variants and methods of using same
WO2002055560A3 (fr) Anticorps monoclonaux specifiques a la glycoproteine e2 du virus de l'hepatite c et leurs utilisations dans le diagnostic, le traitement et la prevention de l'hepatite c
WO2003014728A1 (fr) Medicaments contre l'hepatite c
ATE472337T1 (de) Pharmazeutische zusammensetzung aus f(ab) 2- fragmenten von antikörpern und verfahren zu ihrer herstellung
WO2004014936A3 (fr) Melange de peptides issus des proteines c et ns3 du virus de l'hepatite c et leurs applications.
WO2000018909A3 (fr) Acides nucleiques et proteines provenant de cenarchaeum symbiosum
WO2004021871A3 (fr) Dosage biologique dans le cas du virus de l'hepatite c
WO2003040341A3 (fr) Anticorps contre le virus de l'hepatite a
EP0516859A4 (fr)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KR KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ OM PH PL PT RO SD SE SG SI SK SL TJ TM TN TR TT UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003519409

Country of ref document: JP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase